Pathios Therapeutics

Pathios Therapeutics, founded in 2017 and headquartered in the United Kingdom, is at the forefront of pioneering therapies to combat cancer using advanced genetic insights. The company's focus is on GPR65, a pivotal immunology target linked with multiple diseases, revolutionizing treatments across a broad cancer spectrum. This initiative, backed by proprietary genetic research, highlights Pathios's commitment to transforming cancer outcomes as per their slogan: "Using human genetics to transform cancer outcomes".

With a recent $25.00M Series B investment dated 18 April 2024, the company is strategically positioned, supported by notable investors like Canaan Partners, Brandon Capital, and Bristol-Myers Squibb. These partnerships strengthen its scientific leadership and operational capability within the M:M Bio ecosystem. Ventures into neuroinflammatory and neurodegenerative disorders further diversify their emerging pipelines, leveraging the broader roles of GPR65 in immune response treatments.